Predictive Study of the Active Ingredients and Potential Targets of Codonopsis pilosula for the Treatment of Osteosarcoma via Network Pharmacology

Table 1

Characteristics of the active ingredients.

Compound	MF	Structure	MW	OB (%)	DL	HL
Stigmasterol	C29H48O	fx1	412.77	43.83	0.76	5.57
Stigmast-7-enol	C29H50O	fx2	414.79	37.42	0.75	6.28
Luteolin	C15H10O6	fx3	286.25	32.00	0.25	15.94
11-Hydroxyrankinidine	C20H24N2O4	fx4	356.46	40.00	0.66	10.80
Perlolyrine	C16H12N2O2	fx5	264.30	65.95	0.27	12.62
Glycitein	C16H12O5	fx6	284.28	50.48	0.24	16.32
Spinasterol	C29H48O	fx7	412.77	42.98	0.76	5.32
Frutinone A	C16H8O4	fx8	264.24	65.90	0.34	19.10
Poriferasta-7,22E-dien-3beta-ol	C29H48O	fx9	412.77	42.98	0.76	5.48
7-Methoxy-2-methyl isoflavone	C17H14O3	fx10	266.31	42.56	0.20	16.89
5-α-Stigmastan-3,6-dione	C29H48O2	fx11	428.77	33.12	0.79	5.19
3-β-Hydroxymethyllenetanshiquinone	C18H14O4	fx12	294.32	32.16	0.41	22.51
Zinc03978781	C29H48O	fx13	412.77	43.83	0.76	5.79
Taraxerol	C30H50O	fx14	426.80	38.40	0.77	2.07
Stigmasterone	C29H46O	fx15	410.75	45.40	0.76	5.65